CONVERGE Post-Approval Study (PAS)

Description

The primary objective of CONVERGE PAS is to evaluate clinical outcomes (peri-procedural and long-term) in a cohort of patients treated during commercial use of the EPi-Sense® Guided Coagulation System or EPi-Sense ST™ Coagulation System to treat symptomatic long-standing persistent atrial fibrillation (AF) patients who are refractory or intolerant to at least one Class I and/or III AAD.

Conditions

Chronic Atrial Fibrillation

Study Overview

Study Details

Study overview

The primary objective of CONVERGE PAS is to evaluate clinical outcomes (peri-procedural and long-term) in a cohort of patients treated during commercial use of the EPi-Sense® Guided Coagulation System or EPi-Sense ST™ Coagulation System to treat symptomatic long-standing persistent atrial fibrillation (AF) patients who are refractory or intolerant to at least one Class I and/or III AAD.

Hybrid Convergent of Epicardial and Endocardial RF Ablation for the Treatment of Symptomatic Longstanding Persistent AF

CONVERGE Post-Approval Study (PAS)

Condition
Chronic Atrial Fibrillation
Intervention / Treatment

-

Contacts and Locations

Newport Beach

Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States, 92663

Clearwater

Baycare Health Systems, Clearwater, Florida, United States, 33759

Atlanta

Emory Saint Joseph Hopsital, Atlanta, Georgia, United States, 30322

Baltimore

MedStar Union Memorial Hospital, Baltimore, Maryland, United States, 21218

New Bedford

Southcoast Hospitals Group, New Bedford, Massachusetts, United States, 02740

Winston-Salem

Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States, 27157

Midlothian

Bon Secours, Midlothian, Virginia, United States, 23114

Seattle

Virginia Mason Medical Center, Seattle, Washington, United States, 98101

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Age ≥ 18 years and \< 80 years at time of enrollment consent;
  • 2. Left atrium ≤ 6.0 cm assessed with Transthoracic Echocardiography \[TTE\] with parasternal 4 chamber view or equivalent imaging modality;
  • 3. Refractory or intolerant to at least one AAD (class I and/or III);
  • 4. Subject has symptomatic (e.g. palpitations, shortness of breath, fatigue) longstanding persistent atrial fibrillation as defined by the 2017 HRS/EHRA/ECAS Guidelines (\> 12 months of continuous AF);
  • 5. Life expectancy \> 12 months; and
  • 6. Provides written informed consent.
  • 1. Patients requiring concomitant surgery such as valvular repair or replacement, coronary artery bypass graft (CABG) surgery and atrial septal defect closure;
  • 2. Left ventricular ejection fraction \< 35%;
  • 3. Pregnant or planning to become pregnant during study;
  • 4. Co-morbid medical conditions that limit one-year life expectancy;
  • 5. Previous cardiac surgery;
  • 6. History of pericarditis;
  • 7. Previous cerebrovascular accident (CVA), excluding fully resolved TIA;
  • 8. Patients who have active infection or sepsis
  • 9. Patients with esophageal ulcers strictures and varices;
  • 10. Patients with renal dysfunction who are not on dialysis (defined as GFR ≤ 40);
  • 11. Patients who are contraindicated for anticoagulants such as heparin and coumadin;
  • 12. Patients who are being treated for ventricular arrhythmias;
  • 13. Patients who have had more than 2 prior left atrial catheter ablations for AF. NOTE: Note: Prior ablations should be limited to failed Pulmonary Vein Isolation (PVI) and no other left atrial lesions;
  • 14. Current participation in another clinical investigation of a medical device or a drug, or recent participation in such a study within 30 days prior to study enrollment;
  • 15. Not competent to legally represent him or herself (e.g., requires a guardian or caretaker as a legal representative);
  • 16. Patient has presence of thrombus in the left atrium determined by intraoperative TEE;
  • 17. Patient exhibits pulmonary vein stenosis in one or more of the pulmonary veins \>50 % stenosis;
  • 18. Planned Left Atrial Appendage Management (LAAM) with an endocardial implantable device during the course of the study;
  • 19. Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results
  • 20. Presence of Barretts esophagitis

Ages Eligible for Study

18 Years to 80 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

AtriCure, Inc.,

Study Record Dates

2025-12-31